All In Biotech

Drug Trial Radar · NCT00477503

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Phase 1 Study Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Last checked: Nov 19, 2026Latest source record: Aug 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

May 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. * Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.

Conditions

  • Central Nervous System Tumors
  • Brain Tumors

Interventions

  • Gallium-67 Citrate (Ga-67)Drug

    Group A: Ga-67 citrate injection alone, in the baseline study. Group B: Ga-67 and In 111 DTPA injection in the baseline study. Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

  • In-111 DTPA (In-111 pentetate)Drug

    Group B: Ga-67 and In 111 DTPA injection in the baseline study. Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare Ga-67 citrate with a standard radioactive dye in order to learn if Ga-67 citrate can help doctors to check the flow of CSF for any blockage.Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.